 This study evaluated the effectiveness of SARS-CoV-2 vaccinations in patients with multiple sclerosis, MS, who are typically treated with various disease-modifying therapies, DMTs. The study found that patients on Fingolomod and anti-CD-20 therapy had a significantly lower humoral response compared to those treated with other DMTs and untreated patients. Additionally, the study showed that patients on Fingolomod had lower levels of interferon gamma, ifangama, when tested for their T-cell response to SARS-CoV-2. However, the study also found that most patients on DMTs were not treated with any DMTs still had high levels of protection from the virus. Overall, this study suggests that SARS-CoV-2 vaccinations can be effective in patients with MS, regardless of which DMT they are taking. This article was authored by Susanna Sainz de la Masa, Paulette Esperanza Willo Delgado, Mario Rodriguez Dominguez, and others.